Introduction:

Duchenne Muscular Dystrophy Treatment Market was valued at US$ 2.1 Billion in 2024 and is projected to grow at a CAGR of 42.10% to reach US$ 71.1 Billion by 2034.

[PDF] Duchenne muscular dystrophy is a genetic disorder, which is a severe form of muscular dystrophy. Muscular dystrophies are a group of diseases that rigorously affect the muscles, making them gradually weaker and less flexible. This is a genetic disease caused by the mutation of the genetic factor dystrophin (a protein in the muscles).

The rising prevalence of patients suffering from Duchenne muscular dystrophy is the key factor leading to the growth of the target market. The increasing prevalence of humans getting exposed to mutagens like numerous chemicals, radiation, and various other infectious agents is the reason for these dangerous mutations. This eventually leads to an emerging demand for safe and effective drugs and therapies against this disorder, which in turn helps boost the growth of the Duchenne Muscular Dystrophy Treatment Market. For instance, according to the National Organisation for Rare Disorders, it is reported that one in every 3500 male babies worldwide is born with Duchenne muscular dystrophy. Overall, around 250,000 individuals have been affected by this disorder since birth

Increase in burden of the Duchenne muscular dystrophy treatment market to augment the     market growth

One of the major key factors helping to expand the target market growth is the increase in burden of the DMD (Duchenne Muscular Dystrophy) market due to the rising prevalence of Duchenne muscular dystrophy across the world. This leads to a high demand for effective drugs and treatments, eventually leading to the growth of the Duchenne Muscular Dystrophy Treatment Market.

For instance, according to the National Organization for Rare Disorders (NORD), Duchenne muscular dystrophy has become one of the most common and frequent genetic disorders, affecting around one in every 3500 male births. It has been stated that around 20,000 children are affected by DMD (Duchenne Muscular Dystrophy) across the world each year.

The increase in the demand for novel drugs and therapies

Another major factor that is boosting the target market growth is the high demand for new drugs and therapies for DMD (Duchenne Muscular Dystrophy). The rising awareness among the people is in turn increasing the demand for new and effective drugs and treatments.

For instance, numerous industries in the market have been focusing on the production of novel drugs and therapies for the treatment of DMD (Duchenne Muscular Dystrophy). Further, in August 2020, NS Pharma received FDA (Food and Drug Administration) approval for their drug "Viltepso", which they launched for the treatment of DMD (Duchenne Muscular Dystrophy).

Restrains:

The key factor restraining the growth of the target market is the low rate of treatment of DMD (Duchenne Muscular Dystrophy) due to the delayed diagnosis of the disease. The delay in the diagnosis of this disease is due to the fact that there is a delay of about 2.5 years between the onset of this disease and the time of the definitive diagnosis. This delay leads to insufficient time for appropriate genetic counselling as well as the initiation of corticosteroid treatment.

For instance, according to a study mentioned in PubMed (NCBI), the first signs and symptoms in 156 boys without a known family history of DMD (Duchenne Muscular Dystrophy) were noted at a mean age of 2.5 years, and the mean age at the time of definitive diagnosis was around 4.9 years.

Duchenne Muscular Dystrophy Treatment Market is segmented based on By Therapeutic Approach and Treatment Type, By End-User, and By Region.

Therapeutic Approach and Treatment Type Insight

By Therapeutic Approach and Treatment Type, the Duchenne Muscular Dystrophy Treatment market is classified into molecular-based therapies (mutation suppression and exon skipping), steroid therapy (corticosteroids), nonsteroidal anti-inflammatory drugs (NSAIDs), and other therapeutic approaches and treatment end users. The Molecular-Based Therapies (Exon Skipping) segment is expected to dominate the target market growth as a majority of the exon skipping drugs have been undergoing Phase 3 clinical trials.

 End-User Insights

By End-User, the Duchenne Muscular Dystrophy Treatment Market is classified into Hospitals/Clinics, Ambulatory Centres, and Other End Users. The Hospitals/Clinics segment is expected to dominate the growth of the target market, as it has been owing to the increase in prevalence or burden of DMD (Duchenne Muscular Dystrophy), as well as due to increasing number of patient admissions.

Regional Insights:

On the basis of Region, the Duchenne Muscular Dystrophy Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is expected to dominate the target market growth owing to the emerging awareness about DMD (Duchenne Muscular Dystrophy), the growing public and private health care insurance coverage, improved healthcare facilities with skilled medical staff, improved R&D (research and development) activities, presence of prominent key players, and more government investment in the healthcare system is anticipated to increase the demand for Duchenne Muscular Dystrophy Treatment Market in the Asia Pacific region.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 – 2034
Market Segmentation	By Therapeutic Approach and Treatment Type - molecular-based therapies (mutation suppression, and exon skipping), steroid therapy (corticosteroids), nonsteroidal anti-inflammatory drugs (NSAIDs) and other therapeutic approaches and Treatment End Users By End-Users - hospitals/clinics, ambulatory centres, other end users
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 – 2034. For the purpose of this study, has segmented the Duchenne Muscular Dystrophy Treatment Market report based on By Therapeutic Approach and Treatment Type, By End-User, and By Region:

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment:

• Molecular-Based Therapies (Mutation Suppression, and Exon Skipping)
• Steroid Therapy (Corticosteroids)
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
• Other Therapeutic Approaches and Treatment End Users

Duchenne Muscular Dystrophy Treatment Market, By End-Users:

• Hospitals/Clinics
• Ambulatory Centers
• Other End Users

Duchenne Muscular Dystrophy Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the Duchenne Muscular Dystrophy Treatment Market include BioMarin, Bristol-Myers Squibb Company, Fibrogen Inc., Eli Lilly and Company, Nobelpharma Co. Ltd., NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics.

• BioMarin*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bristol-Myers Squibb Company
• Fibrogen Inc.
• Eli Lilly and Company
• Nobelpharma Co. Ltd
• NS Pharma Inc.
• Pfizer Inc.
• PTC Therapeutics
• Santhera Pharmaceuticals
• Sarepta Therapeutics. 

“*” marked represents similar segmentation in other categories in the respective section

Recent Development:

• In January 2023, Regenxbio started signing up patients for the Phase 1/2 clinical trial to evaluate the security and efficacy of RGX-202, which is an experimental gene therapy for DMD (Duchenne Muscular Dystrophy). In addition, Regenxbio has been looking for DMD (Duchenne Muscular Dystrophy) patients around 12 years of age or younger for an observational study to check for antibodies to the viral vector utilized in the therapy.
• In February 2021, the US FDA (Food and Drug Administration) approved a drug named "Amondys 45 (casimersen)," which is an injection for the treatment of DMD (Duchenne Muscular Dystrophy). Patients with Duchenne muscular dystrophy (DMD) who have a dystrophin gene mutation and that can be corrected by skipping exon 45 are treated with AMONDYS 45.
• Based on an increase in dystrophin production in skeletal muscle shown in patients treated with AMONDYS 45, this indication has been given expedited approval.
• In August 2020, NS Pharma received an FDA (Food and Drug Administration) approval for their drug "Viltepso", which they launched for the treatment of DMD (Duchenne Muscular Dystrophy). It is administered as a concoction into the bloodstream.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Therapeutic Approach and Treatment
     • Market Snippet, By End User
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Molecular-based Therapies (Mutation Suppression, and Exon Skipping)
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Steroid Therapy (Corticosteroids)
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Other Therapeutic Approaches and Treatment End Users
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
6. Duchenne Muscular Dystrophy Treatment Market, By End User, 2022 – 2032, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Hospitals/Clinics
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Ambulatory Centers
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Other End Users
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
7. Duchenne Muscular Dystrophy Treatment   Market, By Region, 2022 – 2032, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Therapeutic Approach and Treatment, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Therapeutic Approach and Treatment, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Therapeutic Approach and Treatment, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

• • Latin America
    • Market Size and Forecast (US$ Bn), By Therapeutic Approach and Treatment, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
• • • • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Therapeutic Approach and Treatment, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032

1. • • • GCC
       • Israel
       • South Africa
       • Rest of Middle East
2. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
3. Company Profiles

 

• BioMarin
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Fibrogen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Nobelpharma Co. Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• NS Pharma Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• PTC Therapeutics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Santhera Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sarepta Therapeutics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact